Physiomics Share Price (PYC)

Trade Now

 Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Physiomics Plc LSE:PYC London Ordinary Share GB00BDR6W943 ORD 0.4P
  Price Change % Change Share Price Shares Traded Last Trade
Upgrade Icon
  0.10 3.64% 2.85 159,940 08:05:25
Bid Price Offer Price High Price Low Price Open Price
2.70 3.00 2.85 2.75 2.75
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.70 -0.34 -0.22 3
Last Trade Time Trade Type Trade Size Trade Price Currency
15:48:49 O 29,899 2.742 GBX
Related Shares
Smith & Nephew (SN.), Convatec (CTEC), Salvarx (SALV), Sensyne Health (SENS)

Physiomics (PYC) Latest News

Physiomics News

Date Time Source Headline
07/7/202216:48ALNCTRADING UPDATES: Michelmersh Brick, Mattioli Woods on-track for growth
07/7/202207:00UKREGPhysiomics PLC Trading update
04/5/202207:02RNSNONPhysiomics PLC Physiomics expands technical team
29/4/202210:00UKREGPhysiomics PLC Issue of Options
08/4/202211:11ALNCIN BRIEF: Physiomics wins new contract for Virtual Tumour platform
08/4/202207:00UKREGPhysiomics PLC Contract award
29/3/202207:01UKREGPhysiomics PLC Appointment of Independent Non-Executive Director
07/3/202214:55ALNCIN BRIEF: Physiomics confident for full-year, in talks for new client
07/3/202207:00UKREGPhysiomics PLC Interim Results
02/3/202220:28ALNCTRADING UPDATES: MediaZest virus hit; SpaceandPeople Network Rail deal
More Physiomics News
Physiomics Investors    Physiomics Takeover Rumours

Physiomics (PYC) Discussions and Chat

Physiomics Forums and Chat

Date Time Title Posts
12/8/202214:29Physiomics - Cancer Treatment tech firm working with Merck + Oxford Uni10,180
17/6/202107:23PHYSIOMICS plc Virtual Tumor platform4,957
28/3/202122:05Physiomics PYC 2021 DISCUSSION (MODERATED)5
22/12/202011:363 Years ago today2
29/11/202014:533 Years ago today-

Add a New Thread

Physiomics (PYC) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Physiomics trades in real-time

Physiomics (PYC) Top Chat Posts

DateSubject
13/8/2022
09:20		Physiomics Daily Update: Physiomics Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker PYC. The last closing price for Physiomics was 2.75p.
Physiomics Plc has a 4 week average price of 2.55p and a 12 week average price of 2.55p.
The 1 year high share price is 7.20p while the 1 year low share price is currently 2.55p.
There are currently 97,424,778 shares in issue and the average daily traded volume is 680,338 shares. The market capitalisation of Physiomics Plc is £2,776,606.17.
Read Full Thread
Reply
05/8/2022
16:55		davevt: Nothing happens to pyc unless VAL can get fda approval, and goes to market, which is years away, and then anything pyc gets is in lieu of what's owed to them for the past 10 years working for VAL for free...and then it's just a one off royalty...it doesn't change the fundamentals of the company other than cash in bank...the day after it's still a loss making company.
Read Full Thread
Follow
Reply
31/5/2022
17:03		share14: Fryup appears to be single handedly supporting the share price
Read Full Thread
Follow
Reply
24/5/2022
13:39		davevt: Because he has been head of PYC for a few years and hasn't managed to get either on board. Not that it makes any difference who the clients are, but it goes to show that clients do not want to work with pyc. Continue 'what' when they left off? Pyc did a dose trial for them, it came to nothing, they said it won't generate any revenue.
Read Full Thread
Follow
Reply
04/5/2022
14:20		the stigologist: Why This 6-Employee Biotech's Stock Jumped 2,000% in Just Three Days Published: Dec 01, 2017 By Alex Keown One day after Bloomberg highlighted a 6,000 percent spike in share prices over three days for U.K.-based Physiomics PLC, the stock is down more than 50 percent this morning, falling to £8.00 per share. The stock rally began on Tuesday with prices climbing from 95 cents per share to a high of £25 per share on Thursday. The spike began after the six-person company announced it had entered into a multi-year services agreement with Germany-based Merck KGaA. The German company said it intended to use Physiomics’ virtual tumor platform to simulate the effect of anti-cancer drugs. Physiomics said it had been working with Merck KGaA since 2012 and had completed 12 projects involving pre-clinical and clinical predictions. Other projects are in progress, the company said on Tuesday. Physiomics said the deal with Merck validates of the company’s Virtual Tumor. In the announcement, Physiomics said it believes its ability to “successfully model the combination effect of treatments having different mechanisms of action at the cellular level and its ability to scale this up to allow meaningful predictions of overall tumor growth” provided unique and valuable insights. Following the initial announcement of the agreement with Merck, the share prices for the tiny U.K, company soared. On Thursday, Physiomics issued a cautionary statement that the agreement with Merck KGaA may not be worth more than the €500,000 ($596,000) over the first 12 months. The company said it believes the agreement represents a key milestone between the companies and “reflects the value that it has been able to add over five years of working with this key client.” The €500,000 is equivalent to about 60 percent of Physiomics’ net operating expenses for the financial year ended June 30. When the deal with Merck KGaA was announced, Physiomics Chief Executive Officer Jim Millen said: "We are very proud to be working with Merck, one of the world's top pharmaceutical companies, in an area as important and rapidly growing as oncology, and we believe this agreement marks the beginning of a new, longer-term relationship with this important client." Physiomics’ Virtual Tumor platform provides several key benefits, including the potential to improve response and survival rate in the clinic through enhanced drug potency. Additionally, the company said it believes the platform will transform clinical decision making in terms of dose and scheduling, as well as provide a greater understanding in how changes in scheduling and doses of drug combinations affects the “dynamics of tumor burden.” htTps://www.biospace.com/article/unique-why-this-6-employee-biotech-s-stock-jumped-2-000-percent-in-just-three-days/
Read Full Thread
Follow
Reply
17/4/2022
20:32		davevt: That's not actually down to Merck. Pyc charge around 35k for a pre clinical modelling job and around 140k for a clinical (a clinical model is the next step after the drug has been through a pre clinical model first) Merck or anyone can't give pyc multi year contracts, as all pyc does is dose predictions for cancer drugs in trials. If Merck have only invented say 3 working cancer drugs, that's all they can give them. Pyc dictate the price, not the clients, and the reason they charge so little is to grab business. Merck will do dose prediction themselves obviously, but if a company comes along and says they can do it Cheaper and allow you to not use up your own resources, why not...?
Read Full Thread
Follow
Reply
17/4/2022
13:40		share14: All that has to happen is Merck decides they should bring the work PYC is doing in-house and that's the end of it. It happens all the time with these large companies, someone new comes in and decides they'll make a name for themselves cutting costs or doing something different. Merck haven't given PYC long term stability with multi year contracts, nor allowed them to profit from the short term ones. Tells you how much they value them. Imagine your boss is coining it but won't pay you enough salary to live without getting a pay day loan at the end of the month or give you a full time contract. You have no other options so you can't tell him to stick it. It seems like Merck have had PYC bent over unable to negotiate anything decent off them as PYC is reliant on them for their existence. They've just allowed them to keep the lights on.
Read Full Thread
Follow
Reply
16/4/2022
14:56		share14: Going by those figures PYC with a generous estimate receive about 0.003% of Mercks sales which is insignificant to Merck but significant to PYC. If Merck were to cut PYC off that would be the end of PYC. They keep saying it's a low risk company but relying on single client when you don't make a profit is about as high risk as it gets.
Read Full Thread
Follow
Reply
09/3/2022
10:54		davevt: Tees, you're an example of someone that hasn't researched what pyc do or charge. Pretty much all of their customer are large pharmaceutical, because who else is doing cancer drugs? And pyc have been around 20 YEARS, that's how old their tech is....you think all the biggest pharma don't know who pyc is and have already been approached by them? The thing is pyc charge 35 grand per pre clinical model, and 140 for clinical, which takes a few years after a pre clinical model. We can work out how much the companies revenues are in advance. The irony is the reason why pyc has so little customers and revenues is because most pharmaceutical companies are using other more advanced companies for the modelling pyc offer. Even Merck, pycs main customer has announced it's teamed us with a new company for DDR modelling..
Read Full Thread
Follow
Reply
21/2/2022
22:30		davevt: I love how riddler parrots pycs claim of 'no one has more expertise in ddr modelling than pyc'.... Yet.. 'DNA damage response (DDR)-focused Artios Pharma has signed a global strategic collaboration with the Merck Group to discover and develop multiple precision cancer drugs.' Merck is pycs biggest client and the one it relies on for the majority of it's revenue, yet they didn't use pyc for ddr... All that's next is Merck drops pyc altogether..
Read Full Thread
Follow
Reply
27/10/2021
22:33		davevt: No it doesn't Stig. All pyc do is work out doses for cancer drugs. They don't 'develop' drugs. They work out how much to give a patient of an already developed drug. That's it. Every other precision dosing company in the world is leagues ahead of pyc and does it for all drugs, not just cancer drugs. That's why they have all the customers and all the work, and pyc has had only 3 new clients in 3 years, by pyc offering work to them for loss making prices. pyc doesn't have any ip as their patents are over 20 years old and expired many years ago...not that they are relevant any more...they are still using 20 year old technology. Pyc has done for tabula nothing more than it does for usual clients. Worked out a dose model for a drug. Instead of a normal client using this for their own drug, tabula are just adding it to it's app so doctors know how much to give a patient. We know pyc charge about 35k for this service. It's tricky to know if this whole trial isn't just smoke and mirrors. Dosemerx IS a dosing app...with loads of drugs already on it, including cancer drugs. Some company will have already done that work for them, so there isn't any real logical reason for tabula to use pyc on this drug, other than they already had the data, or pyc just begged to do it for them for an rns.
Read Full Thread
Follow
Reply
Physiomics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
PYC
Physiomics
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220813 15:12:31